International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Auteurs : Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A
Année : 2020
Journal : Lancet Oncol
Volume : 21
Pages : e83-e96

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Auteurs : Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Auteurs : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Année : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 174-181.e3

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Auteurs : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M, Sotiriou C, Jamieson SMF
Année : 2020
Journal : Br J Cancer
Volume : 122
Pages : 603-612

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Auteurs : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Année : 2020
Journal : Eur J Cancer
Volume : 125
Pages : 69-82

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Auteurs : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Année : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Auteurs : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Auteurs : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Progress in adjuvant systemic therapy for breast cancer.

Auteurs : Pondé NF, Zardavas D, Piccart-Gebhart M
Année : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pages : 27-44

Mammaprint™: a comprehensive review.

Auteurs : Brandão M, Pondé N, Piccart-Gebhart M
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 207-224

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1018

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1180

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Auteurs : Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1181

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Auteurs : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Auteurs : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : EBioMedicine
Volume : 39
Pages : 226-238

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Auteurs : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Auteurs : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : JCI Insight
Volume : 5

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Auteurs : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart-Gebhart M, Gnant M, Baselga J, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Auteurs : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Année : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 169-177